Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**3-Acetylpyridine adenine dinucleotide (APAD)** is a synthetic analogue of nicotinamide adenine dinucleotide (NAD). It consists of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by a pyrophosphate linkage, with the nicotinamide moiety replaced by a 3-acetylpyridine group. Like NAD, it acts as an electron carrier in enzymatic redox reactions and can be alternately oxidized and reduced. APAD is widely used as an experimental coenzyme in biochemical research, particularly for studying dehydrogenase enzyme mechanisms and kinetics. It serves as a substrate or inhibitor for various dehydrogenases, including those involved in bacterial and mammalian metabolism[1][2][5][7]. Its altered structure compared to NAD affects its binding properties and suitability as a substrate for certain enzymes[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-acetylpyridine adenine dinucleotide.